Crown Bioscience Appoints Michael Prosser as Chief Business Officer and Illustrates New Investments in Corporate Leadership

SAN DIEGO, July 28, 2022–(BUSINESS WIRE)–Crown Bioscience, a JSR Life Sciences company, announced today that it has restructured its commercial leadership team by creating a new Chief Business Officer (CBO) position and investing more in business skills.

This press release contains multimedia elements. See the full press release here:

With immediate effect, Michael Prosser is promoted to Chief Business Officer. Michael has been with Crown Bioscience for over ten years, serving in a number of operational and commercial leadership positions and most recently served as Senior Vice President, Commercial and Strategic Development. (Photo: BusinessWire)

With immediate effect, Michael Prosser is promoted to Chief Business Officer. Michael has been with Crown Bioscience for over ten years, holding various operational and commercial management positions. Most recently, he held the position of Senior Vice President for Business and Strategic Development.

The company’s continued growth has resulted in the creation of three new positions within the commercial team who will report to Mr Prosser. Alex Slater, who joined the company last year, leads APAC business development as vice president of global business development; Dr. Jonny McMichael has been named vice president of customer experience and enablement; and Dr. Achim Quandt has joined the company as CEO of Product Management.

“Crown Bioscience has experienced significant growth in recent years, consistently exceeding its annual growth targets, and in the 2021 financial year we were very pleased to record booking growth of over 40%,” said CEO, Armin Spura. “With these changes announced today and Michael’s continued leadership, we are confident that we are building a commercial team that optimally positions Crown Bioscience for our next phase of growth.”

Michael Prosser, CBO, said: “It is an honor to be asked to lead Crown Bioscience’s next phase of business growth. Our success to date is directly attributable to our relentless focus on customer experience, product innovation and setting new industry-leading quality standards, and I am delighted to work closely with this new team and structure as we strive to continually improve all of these areas.”

The company won more than 400 new customers in the 2021 financial year, and to meet this increased demand, it has accelerated investments in its global network, with renovations now completed in APAC laboratories and, in particular, the creation of a joint venture with sister company MBL in Japan . Parallel investments are also planned in Europe and the USA for construction site expansions and strategic acquisitions.


About Crown Bioscience

Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) providing preclinical and translational platforms to advance oncology, immuno-oncology and immune-mediated inflammatory diseases. The company is the only preclinical CRO providing tumor organoid services utilizing HUB technology and has the largest commercially available PDX collection in the global market. Crown Bioscience helps deliver superior drug candidates so patients receive the right treatment at the right time. Crown Bioscience was founded in 2006 and owns nine locations in the US, Europe and Asia. For more information:

The text of the press release, derived from a translation, should in no way be considered official. The only authentic version of the press release is that of the press release in the original language. The translation will always have to be compared with the source text, which will set a precedent.

See the source version at


Crown Bioscience
Louise Stenson

Leave a Comment